Skip to main content
. 2015 Feb 12;3(1):22–26. doi: 10.1016/j.prnil.2015.02.005

Fig. 2.

Fig. 2

Secondary endpoints. (a) Median (interquartile range) serum testosterone (ng/mL) and (b) median (interquartile range) percentage change in serum prostate-specific antigen (PSA; ng/mL), over time in patients receiving degarelix 240/80 mg in CS42 and CS21 (240/80 mg, non-Asian patients; full analysis set).